On this page
What it is
A synthetic non-selective analogue of alpha-melanocyte-stimulating hormone. Bremelanotide is one of its metabolites, developed specifically because a narrower receptor profile was wanted.
How it is proposed to work
Broad agonism across melanocortin receptors. MC1R activation drives melanogenesis, which produces the tanning effect; MC4R activation produces the sexual and appetite effects. The non-selectivity is the whole problem — the effects people want and the effects they do not come from the same drug acting on different receptors, and cannot be separated.
Approved medical uses
None. Melanotan II has no approved human medical indication in the jurisdictions we track. Any use is outside an approved label.
Human research
Each entry states what the study found and, separately, what it cannot show.
- Narrative review2017
Review of reported melanocytic change with unregulated melanotan use
Finding. A review of the risks of unregulated melanotan I and II use reports that increasing numbers of case reports associate their use with cutaneous complications, particularly melanocytic changes in existing moles and newly emerging (dysplastic) nevi, and that four case reports describe melanomas emerging from existing moles either during or shortly after melanotan use. The review also states that conclusive evidence linking these phenomena is lacking, and that multiple national health organisations have issued safety warnings about melanotan I and II.
Limitation. A review rather than a primary study: it summarises published case reports instead of collecting cases itself, the abstract states no search strategy or inclusion criteria, and case reports cannot establish causation. The review itself says conclusive evidence linking melanotan use to these melanocytic changes is lacking, and notes that melanotan is part of a 'tanning culture' in certain subpopulations — so higher UV exposure is an alternative explanation these reports cannot rule out. It treats melanotan I and II together, so the reports it counts cannot be attributed to melanotan II alone. Its value here is that it records the accumulation of reports and the safety warnings issued by multiple national health organisations.
- Case report2012n = 1
Case report of systemic toxicity and rhabdomyolysis after injection
Finding. A man presented two hours after injecting melanotan II bought over the internet, at what he reported as six times the recommended starting amount, with "diffuse body aches, sweating, and a sensation of anxiety", along with mydriasis, diaphoresis, tachycardia and diffuse muscle tremors. He developed rhabdomyolysis with renal dysfunction, and his creatine kinase rose further over the next twelve hours in intensive care. He was given benzodiazepines for agitation and anxiety, with improvement in his symptoms, and intravenous fluids with sodium bicarbonate; creatine kinase and creatinine had both fallen by discharge from intensive care after three days. The injected material was analysed by mass spectrometry and "confirmed to be Melanotan II when compared with an industry purchased standard sample".
Limitation. A single patient, who reported injecting several times the recommended starting amount, so the report cannot show how often this happens or what ordinary use produces. The source also records a urine drug screen negative for cocaine and amphetamine metabolites but positive for opiates, a documented co-exposure that further limits attribution of the sympathomimetic picture to the drug. A case report cannot establish that the drug caused the events, although the analytical confirmation of the injected material removes one of the usual doubts about internet-sourced products.
Preclinical research
Animal and laboratory work. Useful for generating hypotheses; it cannot establish that something works in people.
No preclinical studies catalogued.
Potential safety concerns
- SeriousPromising
Documented changes to pigmented lesions, including new and darkening naevi, with reported melanoma cases in users. Dermatological review before and during use is a reasonable precaution — this is an evidence-backed concern, not a speculative one.
- SeriousPromising
Priapism has been reported. A sustained erection beyond a few hours is a urological emergency requiring immediate care, and delayed presentation risks permanent damage.
- CautionPromising
Nausea, flushing and spontaneous erections are common enough that pre-emptive anti-emetic use is normal community practice.
- SeriousEstablished
Being a metabolite relationship with an approved drug provides no safety reassurance. Bremelanotide's approval says nothing about melanotan II, and treating them as interchangeable substitutes is the most dangerous error in this area.
Known interactions and contraindication considerations
- Blood-pressure effects are relevant alongside antihypertensives and PDE5 inhibitors.
- Not otherwise characterised in humans.
This list is not exhaustive and is not a substitute for a clinician reviewing your full medication history.
Regulatory status
Status is shown per jurisdiction and is accurate only as of the date stated. Where a compound is approved, the approval is bound to a specific formulation, manufacturer and indication — shown in the detail column.
| Jurisdiction | Standing | Detail |
|---|---|---|
United States FDA | Not approved as of 1 Jun 2026 | Not approved. Regulatory authorities have warned against products containing it. |
European Union EMA | Not approved as of 1 Jun 2026 | Not approved. Several national authorities have issued public safety warnings. |
India CDSCO | Unapproved / investigational as of 1 Jun 2026 | Not approved for human use. |
United Kingdom MHRA | Not approved as of 1 Jun 2026 | Not approved, and the subject of public safety warnings from the medicines regulator. |
Australia TGA | Not approved as of 1 Jun 2026 | Not approved, with public warnings issued regarding its use. |
How it is being used
What the grey community actually runs, the reasoning they give, and our read on whether it follows from known biology. This is observation, not evidence, and not a recommendation.
Sexual arousal and spontaneous erections
What is run
Episodic use ahead of anticipated activity, often after an initial period of more frequent administration. Users commonly report the erectile effect appearing well before any pigmentation change, which is why the two uses get separated in practice even though it is one molecule.
Their mechanistic reasoning
That melanocortin-4 receptor activation in the central nervous system drives arousal directly, rather than acting on vascular smooth muscle the way PDE5 inhibitors do — so it is expected to work for people whose problem is desire rather than blood flow, and to work independently of erectile mechanics.
Reported in the community’s own terms. Not our position.
Stacked with
- PDE5 inhibitors—Combined for what is described as complementary central and vascular action. Both can lower blood pressure, and that interaction is the reason this combination deserves a clinician's input.
- Anti-emetics, taken pre-emptively—Nausea is common enough that pre-medicating is normal practice — which is itself a signal about how reliably the effect occurs.
Regimen shape
- Dose
- figure withheld
- Scale
- Microgram to low milligram-scale
- Route
- Subcutaneous injection
- Frequency
- Episodic, as-needed rather than scheduled
- Timing
- Some hours before anticipated activity
- Duration
- Discrete single uses, not a course
Our read
The MC4R arousal mechanism is real and is the same pathway that earned bremelanotide an approval, so the reasoning is not invented. What does not follow is safety by association. Bremelanotide was developed as a narrower-profile metabolite precisely because non-selective melanocortin agonism brings MC1R pigmentation effects and broader activity along with it. Choosing the non-selective parent to save money means accepting every effect the selective version was designed to avoid.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
Widely regarded as reliably effective for this specific purpose, and notably the effect is described as unmistakable rather than subtle — which is unusual in this category and makes reports harder to dismiss as expectation alone. Dissent focuses on tolerability rather than on whether it works.
Commonly reported as helping
- Increased spontaneous arousal, described as beginning hours after administration
- An effect on desire rather than mechanics, which people distinguish from PDE5 inhibitors
- Reported to work for some people for whom PDE5 inhibitors did not
Also reported, when it goes wrong
- Nausea, frequently severe enough that people pre-medicate or abandon use
- Facial flushing and lethargy after dosing
- Unwanted pigmentation changes, including freckling, reported as a common reason for stopping
- Erections described as inconvenient in their timing and duration
Why these reports can mislead
This is one of the few uses where the reported effect is strong and specific enough to be hard to explain by expectation alone. The more relevant caution is different: people report on whether it worked, not on what happened to their skin over the following years. Positive reports are short-horizon; the documented risks are long-horizon, and no forum tracks that.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- A sustained erection beyond a few hours is a urological emergency, not something to wait out. Priapism has been reported and delayed presentation risks permanent damage.
- Blood-pressure effects matter when combined with a PDE5 inhibitor or any antihypertensive.
- The pigmentation effects arrive whether or not you want them — the receptor selectivity that would prevent that is exactly what this molecule lacks.
Tanning and pigmentation
What is run
A more frequent initial phase until the desired pigmentation develops, then a reduced maintenance frequency. Almost always paired with deliberate UV exposure, which is the part of the protocol that most affects the risk picture.
Their mechanistic reasoning
That MC1R activation on melanocytes drives eumelanin synthesis, producing tanning with less UV exposure than would otherwise be needed — framed as photoprotective, since eumelanin does absorb UV.
Reported in the community’s own terms. Not our position.
Stacked with
- Deliberate UV exposure, sunbeds or sunlight—Used to accelerate and deepen the effect. This is the single most consequential element of the protocol and the one that most undermines the photoprotection argument.
Regimen shape
- Dose
- figure withheld
- Scale
- Microgram to low milligram-scale
- Route
- Subcutaneous injection
- Frequency
- Daily during an initial phase, then reduced to maintenance
- Timing
- No consistent convention; often evening to sleep through the nausea
- Duration
- Loading phase then indefinite maintenance
Our read
The MC1R melanogenesis mechanism is correct, and the original research interest in this class genuinely was photoprotection. The reasoning breaks at the practical step: community protocols pair it with UV exposure to accelerate the effect, so the actual behaviour increases UV dose rather than reducing it. That inverts the stated rationale. And it does this while stimulating melanocytes — the cell type from which melanoma arises — which is why the documented reports of changing naevi in users are difficult to dismiss as coincidence even though case reports cannot prove causation.
What the community reports
The comparison is between how sure the community is and how much is actually known — evidence strength, not direction. A compound can have solid research that came out negative.
Regarded as clearly effective at producing pigmentation, and users are generally accurate about the mechanism. Where the discussion goes wrong is safety framing — the photoprotection argument is repeated widely while the protocols themselves involve deliberate UV exposure.
Commonly reported as helping
- Pigmentation developing faster and deeper than with sun exposure alone
- Tanning reported in people who normally burn rather than tan
- Effect persisting for some time after stopping
Also reported, when it goes wrong
- New freckles and darkening of existing moles, reported commonly
- Uneven or patchy pigmentation
- Nausea during the more frequent initial phase
- Darkening of areas people did not want darkened
Why these reports can mislead
The reported benefit is visible in a mirror within weeks; the documented risk concerns melanocytic lesions over years. Those are not on the same timescale, so a forum full of satisfied users tells you almost nothing about the thing that actually matters here. The people whose moles were later investigated are not posting tanning updates.
Direct quotations are not published here yet. We will only carry verbatim reports once they are sourced, dated and checked — an unattributed quote is a testimonial, and testimonials are exactly what this section exists to replace.
Watch for, in this use specifically
- Get a baseline skin check and monitor moles. This is one of the few genuinely evidence-backed monitoring recommendations anywhere in this library.
- New, darkening or changing pigmented lesions warrant prompt dermatological review rather than watchful waiting.
- Existing naevi commonly darken. That makes self-assessment of change harder, not easier, which is an argument for professional baseline photography.
Active clinical trials
No registered trials currently tracked for Melanotan II.
What remains unknown
The questions that would change our assessment if they were answered.
- Is the association with melanocytic change causal, or confounded by UV-seeking behaviour in users? The question is unresolved and the precautionary reading is the sensible one.
- What is the long-term dermatological picture with repeated non-selective melanocortin agonism?
References
- 1.Habbema L, Halk AB, Neumann M, Bergman W. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. Int J Dermatol. 2017.PMID 28266027doi
- 2.Nelson ME, Bryant SM, Aks SE. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. Clin Toxicol (Phila). 2012;50(10):1169-73.PMID 23121206doi
Editorial change history
When we change a grade or a regulatory note, we log it here rather than editing quietly.
Dossier created and graded Safety concern. This grade reflects documented human harms, not weak efficacy evidence.
Spotted something wrong? Tell us — we publish corrections.